-

Eurofins to Acquire DNA Diagnostics Center to Grow Genetic Testing Capabilities and Significantly Expand Further Into the Consumer Testing Market

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific (“Eurofins”), a global scientific leader in bioanalytical testing, announces that its subsidiary Eurofins Clinical Testing US Holdings, Inc. has entered into an agreement to acquire DNA Diagnostics Center (“DDC”), a leader in consumer genetic testing. DDC anticipates delivering revenues of over US$55m in 2021.

DDC is one of the most highly accredited genetic-testing laboratories in the world and was founded on the premise that the technological advancements in DNA testing should translate into services that are accessible and affordable to everyone. The company provides comprehensive consumer and legal DNA testing services for paternity and family relationships, fertility, lifestyle, veterinary, and forensics. DDC is an established and trusted consumer focused testing laboratory, with an extensive and global distribution network.

Eurofins believes that consumer genetic testing, to support personalised lifestyle and health awareness is a significant growth opportunity, and this acquisition will support and significantly accelerate Eurofins’ strategy to expand further into this market. DDC has a highly successful and growing test and product menu and will benefit from Eurofins access to additional markets. We also expect leverage from DDC distribution and sales of existing Eurofins testing capabilities into the consumer market for both genetic and other health and wellness related tests.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

For further information:
Investor Relations
Eurofins Scientific
Livia Baratta
Phone: +32 2 766 1620
ir@eurofins.com

Industry:

Eurofins Scientific

BOURSE:ERF
Release Versions
EnglishFrench

Contacts

For further information:
Investor Relations
Eurofins Scientific
Livia Baratta
Phone: +32 2 766 1620
ir@eurofins.com

More News From Eurofins Scientific

Eurofins Supplement Testing and the Eurofins Assurance Network Join SuppCo’s TrustScore® Ranking With Industry-leading Supplement Certifications

MADISON, Wis.--(BUSINESS WIRE)--Eurofins Supplement Testing and the Eurofins Assurance network are pleased to announce that their Certified Dietary Supplement and Clean Sport Certified programs are now incorporated into SuppCo’s TrustScore® supplement quality rating system. This integration strengthens Eurofins Supplement Testing and Eurofins Assurance’s role in third‑party supplement verification and enhances TrustScore® as a comprehensive benchmark, giving brands greater visibility in a marke...

Eurofins Announces the Cancellation of 6.163M Repurchased Shares

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (the “Company” or “Eurofins”) (EUFI.PA) (Paris:ERF) announces that its Board of Directors has decided on the cancellation of 6,163,000 shares, representing 3.38% of the Company’s share capital, that were repurchased as part of its share buyback programmes, which began in October 2022. The cancellation of shares is in line with, among other objectives, the Company’s intention to reduce the share capital as authorised by shareho...

Eurofins Scientific SE: Director/PDMR Shareholding

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM   1. Details of the per...
Back to Newsroom